Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
企業コードTWST
会社名Twist Bioscience Corp
上場日Oct 31, 2018
最高経営責任者「CEO」Dr. Emily M. Leproust, Ph.D.
従業員数923
証券種類Ordinary Share
決算期末Oct 31
本社所在地681 Gateway Blvd.
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94080
電話番号18007190671
ウェブサイトhttps://www.twistbioscience.com/
企業コードTWST
上場日Oct 31, 2018
最高経営責任者「CEO」Dr. Emily M. Leproust, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし